Health

OpenEvidence CEO tells medical students to take paper exams as OpenAI and Anthropic give doctors AI free

Daniel Nadler built a $15 billion company on giving doctors AI answers free. On Monday he warned the doctors still training on his tool that AI erodes the skill that makes an answer worth having.

Vincent JiangVincent Jiangthree-minute read
Share
The OpenEvidence app on a clinician's screen: a question about knee pain answered with a comparison table of ITB syndrome against a lateral meniscal tear, with references to Muscle & Nerve and JAMA and a continuing-education credit panel
OpenEvidence at the point of care, answering a clinical question from licensed literature and logging continuing-education credit. The tool is free to verified doctors and funded by pharmaceutical advertising, the model behind the $15 billion valuation Semafor reported before Nadler's warning.

Paper exams, from the CEO who put AI in the chart

Daniel Nadler, founder and chief executive of the medical-literature search engine OpenEvidence~$6B — OpenEvidence, private, latest valuation ~$6B, told Semafor's Silicon Valley & The World event on November 16 that medical students should "learn the hard way, do paper exams" even if they also use AI 1. "The risk of cognitive offloading is really, really acute," he said, cognitive offloading being the handing of mental work to a machine, and sharpest for students who have studied with AI from the start 1. Semafor put his company's value at $15 billion 1, a mark set by a $250 million September round, earned on advertising revenue, with verified doctors paying nothing 2.

OpenEvidence's valuation climbed from $1 billion to $15 billion in 19 months

Valuation rose 15-fold in 19 months while the product stayed free to doctors

$0B$5B$10B$15BFeb '25Jul '25Oct '25Jan '26Sep '26Raised the month free rivalsgathered
Data
Post-money valuation
Feb '25$1B
Jul '25$3.5B
Oct '25$6B
Jan '26$12B
Sep '26$15B
Post-money valuation by funding round, February 2025 to September 2026; compiled from round reporting collected on Wikipedia (CNBC, NYT, Forbes, Fierce Healthcare).2

Two small studies back the warning

The warning has numbers behind it. A 2025 Lancet study found skilled doctors spotted fewer precancerous growths without AI after months of using it, 22.4% unaided against 28.4% before 1. An MIT Media Lab study of 54 people found the weakest brain connectivity among those writing essays with ChatGPT 1. Both were small 1.

The bite is the deployment: since October 20, OpenEvidence has sat inside NYU Langone Health's Epic medical-record system, reaching 12.4 million outpatient visits a year and more than 6,000 physicians, among them the 2,000-plus residents and fellows training at NYU's two medical schools 3. The cohort Nadler wants on paper already has his tool in the chart.

Free answers from three giants

The same week stacked free supply against that valuation. Anthropic$350B — Anthropic, private, latest valuation $350B, maker of Claude, agreed in September to supply OpenEvidence free to clinicians in about 100 countries, with financial terms undisclosed 4.

On November 15, Apple+0.08% — Apple, up 0.08 percent today put OpenEvidence in front of up to 200,000 U.S. consumers in a health study, no commercial terms disclosed 5, a launch The Inference covered on November 16. A day later, OpenAI$1.18T — OpenAI, private, latest valuation $1.18T loaded more than 20 health plugins into ChatGPT for Healthcare, where ChatGPT for Clinicians is free for eligible U.S. doctors, and priced its GPT-6 Luna admin agent at 8.5 cents a task, 98% below the frontier model 67.

Licensable content is what free answers cannot copy

The defense is scale and licenses. U.S. clinicians consulted OpenEvidence 42 million times in August alone 4, and the company holds content agreements with NEJM, JAMA, Nature, NCCN and Cochrane 8. Licensed clinical content can hold a price where general answers cannot; advertising aimed at doctor screens is what free supply cuts. Before paying the September mark, investors should want the Apple and health-system economics disclosed, and a view on what a pharma ad is worth beside a free ChatGPT. Nadler's own warning prices the risk: the scarce asset is not the answer but the doctor who can check it.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading AAPL

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

    A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

    Health

    Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33

    A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.

    Health

    OpenAI prices healthcare back-office work at 8.5 cents a task, undercutting Ambience Healthcare

    OpenAI's new healthcare agents run prior-authorization work at 8.5 cents a task, and Menlo Ventures says the scribe market's new dollars are going to Microsoft and Epic. Ambience's $37,500-per-doctor receipt is now the only thing it sells that the model layer does not.

    Health

    Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price

    The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results.

    Health

    Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

    James Tobin's November 10 sale left him with zero shares and zero options in Globus Medical, with no trading plan, five days after the company cut its 2026 revenue outlook by up to $130 million. The board's answer was a $500 million buyback increase.

    Health

    Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

    Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

    Subscribe to TheInference for free